Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs

ME Therapeutics Advances mRNA Pipeline Amidst Price Consolidation at $2.50 Support Level

By The Northwire Desk — AI Analysis Apr 29, 2026 · 09:00 METX · 2.5 ME Therapeutics Holdings Inc.
Executive Summary
  • The most recent release (April 29, 2026) provides a scientific update on In Vivo CAR and therapeutic mRNA programs.
  • Key progress includes dose-dependent single agent efficacy for a STING pathway-targeting mRNA candidate in a mouse colorectal cancer model.
  • The company is advancing a dual CD19/CD22-targeted CAR candidate, combining licensed nanobody assets with clinically tested constructs.
  • Lipid nanoparticle (LNP) formulations are being optimized for effective delivery to human T cells and macrophages.
  • Historical context from October 2025 confirms the licensing of exclusive commercial rights to a CD22 nanobody asset from the National Research Council of Canada (NRC).
  • September 2026 data indicates US Patent No. 12,421,308 was secured for the G-CSF antibody candidate, though metadata dates suggest potential reporting inconsistencies regarding patent grant timing versus news release date.
Material Impact
  • The April 2026 update represents incremental progress rather than a fundamental shift in risk profile or valuation drivers.
  • Preclinical efficacy data is positive but does not guarantee clinical success; the market typically discounts early-stage animal model results without Phase 1 initiation announcements.
  • Previous milestones (October 2025 license deal) were already priced into the stock, which subsequently declined from $6.80 to current levels despite the asset acquisition.
  • The news confirms execution on the pipeline strategy but lacks catalysts such as partnership deals, financing closures, or regulatory approvals that would constitute material positive impact.
  • Given the stock has been flat at $2.50 for months leading up to this release, the market appears to view preclinical updates as routine maintenance of the R&D roadmap rather than a re-rating event.
METX · Price
Company Overview
  • ME Therapeutics Holdings Inc. focuses on immuno-oncology, specifically in vivo CAR cell therapy and therapeutic mRNA programs.
  • Flagship Project: Dual CD19/CD22-targeted CAR candidate designed for leukemia, lymphoma, and autoimmune diseases.
  • Secondary Pipeline: STING pathway-targeting mRNA candidate for solid tumors (colorectal cancer).
  • Lead Asset: G-CSF antibody candidate (H1B11-12) with secured US patent protection.
  • Development Stage: Preclinical to early clinical transition; Phase 1 trial (NCT06208735) is ongoing for the CD22 binder under investigator-driven protocols.
Read the original news release →

More from ME Therapeutics Holdings Inc.

Jun 03, 2026 · 15:13

ME Therapeutics raises $500K via private placement to fund R&D and pursue U.S. listing as stock trades near 52-week lows.

Financings Jan 30, 2026 · 16:26

ME Therapeutics talks pipeline and in vivo CAR plans

Other Oct 16, 2025 · 18:53

ME Therapeutics licenses NRC's CD22 nanobody asset

M&A / Property Oct 16, 2025 · 09:00

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

M&A / Property